Shareholder Updates
Shareholder Update April 2021
Apr 28th, 2021
The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – April 2021 is now available to view online.
Read More
Shareholder Update October 2020
Oct 20th, 2020
In this issue:
>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray
>> Rapid progress in the DEP® irinotecan phase 2 & preparations underway for clinical combinations
>> DEP® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models
>> VivaGel® BV launched in Central & Eastern Europe and Nordic region
>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication
>> VivaGel® BV has now been approved in 40 countries with further submissions underway
>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray
>> DEP® docetaxel update & patient case study
>> DEP® cabazitaxel update & patient case study
>> Multiple DEP® products showcased at AACR 2020 Annual Meeting
>> New DEP® partnership signed with Chase Sun for anti-infective program
>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center
>> Starpharma creates slow release soluble DEP® remdesivir
>> DEP® partnering, including Antibody Drug Conjugates
>> DEP® lutetium; impressive efficacy in human prostate cancer model
>> Outlook, Annual Report & ESG Report & recent news
Read More
Shareholder Update May 2020
May 14th, 2020
In this issue:
>> VivaGel® BV launched in Asia
>> Fleurstat BVgel launched in NZ
>> DEP® irinotecan phase 2 commences after positive phase 1 results
>> SPL7013 against SARS-COV-2 (coronavirus)
>> Fleurstat BVgel ranks as #1 topical BV treatment
>> Okamoto adds 11 more Asian countries to licence
>> US regulatory update
>> COVID-19: Starpharma’s operations continue with minimal disruption
>> DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan
>> DEP® patient case studies
>> AstraZeneca’s DEP® trial ongoing in the US & US$3 million milestone payment received
>> New DEP® ADC programs
>> DEP® pipeline targets multiple high-value areas
>> Other DEP® programs
>> Outlook, recent news & events
Read More
Shareholder Update January 2020
Jan 30th, 2020
In this issue:
>> VivaGel® BV launched in the UK
>> AstraZeneca first DEP® product enters the clinic; triggers US$3M milestone
>> DEP® cabazitaxel trial moves into phase 2 on positive results
>> Fleurstat BVgel marketing campaign; New Zealand launch planned
>> Dual strategy to achieve approval of the NDA in the US
>> Okamoto joins forces with Japanese government for STI prevention campaign
>> VivaGel® condom receives regulatory approval in Europe
>> DEP® docetaxel & DEP® cabazitaxel clinical trial case studies
>> DEP® irinotecan phase 1/2 trial
>> New candidate - DEP® gemcitabine
>> GMP DEP® facility licence
>> DEP® combinations add further value
>> Outlook, recent news & events
Read More
Shareholder Update July 2019
Jul 1st, 2019
In this issue:
>> VivaGel® BV launched in Europe & Australia; US regulatory progress
>> VivaGel condom launched in Japan by Okamoto
>> DEP® docetaxel & DEP® cabazitaxel clinical trial update; DEP® irinotecan trial start & new data
>> Starpharma signs second commercial oncology agreement with AstraZeneca
>> AstraZeneca highlights AZD0466 at 2019 ASCO meeting & upcoming US FDA IND
>> Patent published for AstraZeneca Bcl2/xL DEP conjugates
>> DEP® radiotherapeutics
>> Outlook, recent news & events
Read More
Shareholder Update March 2019
Mar 18th, 2019
In this issue:
>> Fleurstat BVgel - Australian launch
>> Mundipharma's European launch of VivaGel® BV
>> Mundipharma's international roll-out of VivaGel® BV
>> FDA meeting to discuss VivaGel® BV approval in the US
Download: Shareholder Update March 2019 (pdf file, 453kb)
Read More
Shareholder Update January 2019
Jan 17th, 2019
In this issue:
>> FDA requests further data for VivaGel® BV approval in the US
>> Launch of VivaGel® BV in multiple territories
>> VivaGel® BV licensed to ITF Pharma in the US
>> VivaGel® condom approved in Japan
>> Clinical trials for internal DEP® products progressing well
>> Patent published for AstraZeneca-DEP® drugs: DEP® Bcl2/xL inhibitors show compelling efficacy & synergy in combination
>> DEP® docetaxel & DEP® cabazitaxel outperformed both gemcitabine & Abraxane®
>> SPL7013 eye drops for viral conjunctivitis
>> Partnering activities
>> Macquarie initiates coverage of Starpharma
>> Outlook
Download: Shareholder Update January 2019 (pdf file, 557kb)
Read More
Shareholder Update February 2018
Feb 19th, 2018
In this issue:
>> New sites open for the DEP® docetaxel phase 2 trial
>> DEP® cabazitaxel phase 1 / 2 trial commences
>> VivaGel® BV NDA submission lodged under Fast Track program
>> VivaGel® BV approved by TGA
>> DEP® irinotecan progressing towards the clinic
>> AstraZeneca-Starpharma collaboration
>> Extensive global licensing negotiations for VivaGel® BV
>> Positive market research findings for VivaGel® BV
>> Q2 Cashflow Report at 31 December 2017
>> OTCQX market recognition
>> Starpharma News & Events
>> Outlook
Download: Shareholder Update February 2018 (pdf file, 1.5mb)
Read More
Shareholder Update October 2017
Oct 18th, 2017
In this issue:
>> DEP® docetaxel achieves positive phase 1 results and commences phase 2
>> AZ presents first DEP® candidate AZD0466 – a Bcl2/xL inhibitor
>> Successful VivaGel® BV phase 3 results
>> Update on other internal DEP® candidates
>> Grant awarded to Starpharma-Monash
>> Starpharma and Peter Mac Cancer Centre awarded grant
>> FY17 Financial results; >$60M cash at 30 June
>> Annual Report and Annual General Meeting
>> Starpharma News & Events
Download: Shareholder Update October 2017 (pdf file, 1.3mb)
Read More
Shareholder Update July 2017
Jul 4th, 2017
In this issue:
>> Starpharma sells Agrochemicals business to Agrium for $35M cash
>> DEP® irinotecan outperforms irinotecan in multiple cancer models
>> DEP® docetaxel, DEP® cabazitaxel and scale-up facilities
>> AstraZeneca pays US$2M DEP® milestone to Starpharma
>> VivaGel® BV phase 3 results timing and commercialisation
>> VivaGel® condom launched in Canada
>> Sale of Ansell's Sexual Wellness division
>> Starpharma News & Events
Download: Shareholder Update July 2017 (pdf file, 710kb)
Read More
Shareholder Update January 2017
Jan 19th, 2017
In this issue:
›› Enrolment completed for phase 3 program: VivaGel® BV for prevention of recurrence
›› VivaGel® BV granted QIDP and Fast Track designation by US FDA
›› Favourable revision to FDA guidance for BV Treatment
›› VivaGel® condom approved in Canada; licensed in China and Iran
›› New DEP® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies
›› DEP® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2
›› DEP® cabazitaxel shows no neutropenia
›› DEP® irinotecan internal program shows superior performance
Download: Shareholder January 2017 (pdf file, 751kb)
Shareholder Update April 2016
Apr 13th, 2016
In this issue:
> Message from the CEO
> Adama licenses Priostar® for 2,4-D
> DEPTM cabazitaxel shows superior performance
> Starpharma's Targeted DEPTM conjugates - compelling results in an area of high interest
> AstraZeneca selects second DEPTM candidate
> Starpharma long standing collaborator ranked 4th in the world
> Starpharma signs licence with Aspen for commercialisation of VivaGel® BV in Australia and New Zealand
> MOU for VivaGel® condom in China
> Half-year financial results
> Bio-Europe® conference
Download: Shareholder Update April 2016 (pdf file, 1MB)
Read More